Long-term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: a 5-year blinded prospective follow-up study

Archives of Dermatology
Bárour SigurgeirssonE Glyn V Evans

Abstract

To examine long-term cure and relapse rates after treatment with continuous terbinafine and intermittent itraconazole in onychomycosis. Long-term prospective follow-up study. Three centers in Iceland. The study population comprised 151 patients aged 18 to 75 years with a clinical and mycological diagnosis of dermatophyte toenail onychomycosis. In a double-blind, double-dummy study, patients were randomized to receive either terbinafine (250 mg/d) for 12 or 16 weeks or itraconazole (400 mg/d) for 1 week in every 4 for 12 or 16 weeks (first intervention). Patients who did not achieve clinical cure at month 18 or experienced relapse or reinfection were offered an additional course of terbinafine (second intervention). The primary efficacy criterion was mycological cure, defined as negative results on microscopy and culture at the end of follow-up and no requirement of second intervention treatment. Secondary efficacy criteria included clinical cure without second intervention treatment and mycological and clinical relapse rates. Median duration of follow-up was 54 months. At the end of the study, mycological cure without second intervention treatment was found in 34 (46%) of the 74 terbinafine-treated subjects and 10 (13%) of the ...Continue Reading

Citations

Nov 28, 2002·The British Journal of Dermatology·B SigurgeirssonE G V Evans
May 15, 2009·The New England Journal of Medicine·David de Berker
Jan 15, 2005·Journal of the European Academy of Dermatology and Venereology : JEADV·R Baran, A Kaoukhov
Jul 22, 2005·International Journal of Clinical Practice·S H Wang, C C Chi
Dec 17, 2009·Photochemistry and Photobiology·Zakhariya ManevitchClaes D Enk
Jan 1, 2009·Clinical, Cosmetic and Investigational Dermatology·Jason G Newland, Susan M Abdel-Rahman
Aug 11, 2004·American Journal of Clinical Dermatology·Aditya K GuptaMaria M Chaudhry
Jun 6, 2009·American Journal of Clinical Dermatology·Peter MayserDebby Budihardja
Nov 3, 2007·Nihon Ishinkin Gakkai zasshi = Japanese journal of medical mycology·Hideomi Shibaki
Feb 16, 2008·Nihon Ishinkin Gakkai zasshi = Japanese journal of medical mycology·Shinobu MohriShigeru Abe
Nov 28, 2009·Nihon Ishinkin Gakkai zasshi = Japanese journal of medical mycology·Yumi Ogawa, Masataro Hiruma
Jul 27, 2011·Medical Mycology Journal·Takashi Harada
Dec 20, 2013·American Journal of Clinical Dermatology·Daniel Coelho de SáAntonella Tosti
May 20, 2008·The Journal of Dermatological Treatment·Robert BaranJavier I Garduno
Feb 10, 2006·The Journal of Dermatological Treatment·Bardur SigurgeirssonRajesh Bakshi
Jun 5, 2014·Expert Review of Anti-infective Therapy·Aditya K Gupta, Deanne Daigle
Aug 19, 2005·Expert Review of Anti-infective Therapy·Adolfo C Fernandez-ObregonCarolyn Willis
May 12, 2009·Expert Opinion on Investigational Drugs·Sandeep Kumar, Alexa B Kimball
Aug 11, 2012·Expert Opinion on Investigational Drugs·Bárdur Sigurgeirsson, Mahmoud Ghannoum
Jun 7, 2005·Expert Opinion on Pharmacotherapy·Robert BaranGerald E Piérard
Jan 8, 2014·Dermatology Research and Practice·Kostas KalokasidisKlaus Fritz
Sep 2, 2005·International Journal of Dermatology·Erin M WarshawDebra D Fett
Nov 12, 2005·Skinmed·Aditya K GuptaElizabeth A Cooper
Dec 18, 2003·Journal of the European Academy of Dermatology and Venereology : JEADV·B Sigurgeirsson, O Steingrímsson
Sep 27, 2003·The British Journal of Dermatology·J H OlafssonR Baran
Mar 20, 2004·The British Journal of Dermatology·A K GuptaA M Johnson
Mar 26, 2003·The British Journal of Dermatology·D T RobertsUNKNOWN British Association of Dermatologists
Jun 20, 2007·Mycoses·C SeebacherUNKNOWN German-speaking Mycological Society
May 16, 2008·Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·Hans Christian Korting, Claudia Schöllmann
Aug 24, 2007·Journal of the European Academy of Dermatology and Venereology : JEADV·M-H Schmid-Wendtner, H C Korting
Jan 19, 2007·Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·Claus SeebacherHans-Jörgen Tietz
Apr 4, 2007·Dermatologic Therapy·Justin J Finch, Erin M Warshaw
Sep 14, 2010·Journal of Clinical Pharmacy and Therapeutics·J ThomasC Sharpe
Apr 1, 2016·Journal of the American Podiatric Medical Association·Tracey C VlahovicBryan C Markinson
Jun 19, 2015·Indian Journal of Dermatology, Venereology and Leprology·Pravesh YadavShukla Das
Mar 31, 2015·Indian Journal of Dermatology·Pravesh YadavShukla Das
Aug 12, 2014·Journal of Foot and Ankle Research·Ivan R Bristow

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.